Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has updated the number of study locations from 104 to 103 and changed the location from Patra, Greece to Guadalajara, Mexico.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check41 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check48 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check56 days agoChange DetectedThe study has added 104 locations, including Long Beach, California, while 116 locations were previously listed, including several hospitals in Greece and Turkey.SummaryDifference5%
- Check63 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.